[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cardiocentro Ticino\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":233},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,72,99,129,161,198],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100638421","phase-3-study-of-the-long-term-effects-of-p2y12-inhibitor-monotherapy-and-coagulation-markers-after-percutaneous-coronary-angioplasty-100638421",false,"NCT07582835","Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.","Hunting for the Long-Term EffeCts of P2Y12 Inhibitor monotHerapy and Coagulation Monitoring After PCI: an Open-label, Randomized Study.","HI-TECH 2","Inclusion Criteria:\n\n* Age ≥18 years\n* Prior (≥3 months) ACS and\u002For PCI\n* Eligible for P2Y12 inhibitor monotherapy after an uneventful DAPT course\n* Free from ischemic (i.e. any new episode of ACS, symptomatic restenosis, stent thrombosis, stroke, any revascularization requiring prolonged DAPT) and\u002For bleeding events (defined as BARC ≥ 2) for at least 3 months\n* Written informed consent.\n\nExclusion Criteria:\n\n* Unconscious patients\n* Unable to provide written informed consent\n* Under judicial protection, tutorship or curatorship\n* Unable to understand and follow study-related instructions or unable to comply with study protocol\n* Known hypersensitivity or allergy to clopidogrel, ticagrelor or prasugrel\n* Severe hepatic impairment\n* Haemoglobin level \\\u003C10 g\u002FdL or platelet count \\\u003C100 000 cells\u002FmL\n* Pregnant or breastfeeding women\n* Life expectancy less than 1 year\n* Active participation in another interventional trial\n* Need for concomitant oral anticoagulation\n* History of intracranial haemorrhage (anytime), transient ischemic attack or stroke within 3 months\n* PCI for in-stent restenosis or stent thrombosis at index PCI or within 6 months before randomization","ALL","18 Years",{"count":20,"type":21},355,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events. After an initial period of dual antiplatelet therapy, long-term treatment with a single P2Y12 inhibitor (such as clopidogrel, ticagrelor, or prasugrel) is often prescribed. However, the optimal drug and dose for long-term monotherapy remain uncertain, as patients may experience either insufficient platelet inhibition (leading to ischemic events) or excessive inhibition (increasing bleeding risk).\n\nThe HI-TECH 2 study aims to identify the most appropriate type and dose of P2Y12 inhibitor monotherapy to achieve a balanced level of platelet inhibition within a predefined therapeutic range. The study also seeks to better understand how blood coagulation activity evolves over time after PCI.\n\nThis is a prospective, investigator-initiated, single-center, open-label study conducted in two phases. In Phase 1, patients receive stepwise reduced doses of ticagrelor or prasugrel to determine the optimal dose that most consistently achieves the desired level of platelet inhibition. In Phase 2, patients are randomly assigned to receive clopidogrel or the optimal doses of ticagrelor or prasugrel identified in Phase 1.\n\nThe main question of the study is whether optimized ticagrelor or prasugrel regimens are more effective than standard-dose clopidogrel in achieving platelet inhibition within the target therapeutic window, as measured by validated platelet function tests. Additional objectives include evaluating the role of genetic factors in treatment response and assessing markers of coagulation activation over time.\n\nThe results of this study may help personalize long-term antiplatelet therapy after PCI, improving the balance between reducing thrombotic risk and minimizing bleeding complications.",[27,28,29,30,31,32],"Coronary Artery Disease","Percutaneous Coronary Intervention","Acute Coronary Syndromes","Antiplatelet Therapy","Single Antiplatelet Therapy","Coagulation Factors",[27,31,34,35,36,37,38,39,40,41,42,29,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58],"Antiplatelet therapy","Ticagrelor","Prasugrel","Coagulation biomarkers","Clopidogrel","Multiplate","VerifyNow","CYP2C19","ABCB1 gene","Dose optimization","platelet function tests (PFT)","Percutaneous Coronary Intervention (PCI)","High platelet reactivity (HPR)","Low platelet reactivity (LPR)","Bleeding Risk","Ischemic risk","prothrombin fragment F1+2","thrombin-antithrombin (TAT) complex","fibrinopeptide A","fibrinogen","D-dimer","von Willebrand factor activity (VWF)","plasminogen activator inhibitor-1 (PAI-1)","thrombin-activatable fibrinolysis inhibitor (TAFI)","circulating extracellular vesicles","RECRUITING","2026-05-06",{"date":62,"type":63},"2026-05-13","ACTUAL",{"date":65,"type":21},"2026-04-20",{"date":67,"type":21},"2028-04",{"name":69,"class":70},"Cardiocentro Ticino","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":71},"100598866","ticino-artificial-intelligence-integration-for-occlusion-myocardial-infarction-100598866","NCT07077057","Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction","TITAN-OMI","Inclusion Criteria:\n\n1. Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder\u002Farm\u002Fjaw\u002Fback, fatigue, or light-headedness\n2. Age: Patients aged 18 years or older.\n3. Informed Consent: Patients able to provide informed consent\n\nExclusion Criteria:\n\n1. Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians.\n2. Pregnancy or Lactation.\n3. Legally incompetent to provide informed consent.\n4. Symptoms onset\\>24 hrs prior to clinical presentation.",{"count":80,"type":21},500,[82],"NA","The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria.\n\nThe main questions it aims to answer are:\n\n1. Does AI-assisted ECG interpretation enable more timely identification and treatment of OMI, as defined by earlier initiation of coronary intervention?\n2. Does AI-assisted diagnosis reduce infarct size, measured by peak high-sensitivity troponin T (hsTnT) levels?\n\nResearchers will compare AI-assisted ECG interpretation to standard care to determine if the AI tool improves clinical outcomes and care timelines.\n\nParticipants will:\n\n1. Present with symptoms suggestive of ACS but without clear STEMI criteria\n2. Be randomized 1:1 to either AI-assisted or standard ECG interpretation\n3. Undergo follow-up assessments for cardiovascular outcomes, including 30-day death, time to treatment of total coronary occlusion, and peak hsTnT levels",[85,86],"Myocardial Infarction (MI)","Acute Coronary Syndrome (ACS)",[88,89,90],"Occlusion Myocardial Infarction","Electrocardiogram","Artificial Intelligence","2026-04-29",{"date":93,"type":63},"2026-05-05",{"date":95,"type":63},"2025-08-23",{"date":97,"type":21},"2027-09",{"name":69,"class":70},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":71},"100632536","minimally-invasive-coronary-artery-bypass-supported-by-cangrelor-100632536","NCT07514962","Minimally Invasive Coronary Artery Bypass Supported by Cangrelor","MINOTAUR","Inclusion Criteria for the historical control arm:\n\n* Age ≥18 years old\n* CABG with IMA-LAD graft in MIDCAB technique\n\nInclusion criteria for the prospective arm:\n\n* Age ≥18 years old\n* CABG with IMA-LAD graft in MIDCAB technique\n* Signed informed consent\n\nExclusion criteria for the historical control arm\n\n* Administration of fibrinolytics or GP IIb\u002FIIIa inhibitors\n* Previous intracranial hemorrhage\n* Known bleeding diathesis\n* Patients undergoing concomitant PCI and MIDCAB\n* Severe renal or liver disease\n* Pregnancy or breast feeding\n\nExclusion criteria for the prospective arm\n\n* Unconsciousness\n* Known hypersensitivity to study drug (cangrelor)\n* Recent administration of fibrinolytics or GP IIb\u002FIIIa inhibitors\n* Previous intracranial hemorrhage\n* Known bleeding diathesis\n* Patients undergoing concomitant PCI and MIDCAB\n* Severe renal or liver disease\n* Pregnancy or breast feeding",{"count":107,"type":21},30,"OBSERVATIONAL","The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.\n\nThe study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand.\n\nStudy Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications?\n\nHypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure.\n\nThis study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.",[27,30,111],"Minimally Invasive Coronary Revascularization Surgery",[113,114,27,115,116,117,118,119,120,48],"Minimally Invasive Direct Coronary Artery Bypass","MIDCAB Surgery","Cangrelor","Perioperative Antiplatelet Therapy","Platelet Function Monitoring","Bridging Therapy","Cardiac Surgery","Intraoperative Antiplatelet Management","2026-04-13",{"date":123,"type":63},"2026-04-14",{"date":125,"type":63},"2024-05-12",{"date":127,"type":21},"2028-01-01",{"name":69,"class":70},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":71},"100602996","comparative-intra-procedural-evaluation-of-farapulse-and-farawave-nav-catheters-100602996","NCT07130773","Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters","Procedural Comparative Evaluation of Pulmonary Vein Isolation Using the FARAWAVE Nav PFA Catheter Without Pre-Ablation Computer Tomography (CT) vs. Conventional Farapulse With Pre-Ablation CT: A Single Centre Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n* Atrial fibrillation (AF) documented on a 12-lead ECG, Holter monitor, or implantable cardiac device.\n* Candidate for ablation according to current atrial fibrillation guidelines.\n* Age ≥18 years at the time of informed consent.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Previous left atrial ablation or left atrial surgery.\n* Presence of intracardiac thrombus.\n* Persistent atrial fibrillation lasting \\>3 years.\n* Severe mitral regurgitation or moderate-to-severe mitral stenosis.\n* Pregnancy (all women under 50 years undergo an HCG blood test prior to inclusion to exclude pregnancy).",{"count":137,"type":21},58,[82],"The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow.\n\nThe FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps.\n\nThese features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure.\n\nOur study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival",[141,142,143],"Atrial Fibrillation (AF)","Atrial Fibrillation Ablation","Pulsed Field Ablation",[145,146,147,148,149,150,151,152],"pulsed filed ablation","atrial fibrillation","ablation","pulmonary vein isolation","electroanatomical map","ionizing radiation","farapulse","farawave nav","2026-03-17",{"date":155,"type":63},"2026-03-19",{"date":157,"type":63},"2025-11-10",{"date":159,"type":21},"2026-12",{"name":69,"class":70},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":178,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":71},"100587476","ticin-pilot-study-sirolimus-eluting-balloon-for-stabilization-and-regression-of-non-obstructive-coronary-plaques-100587476","NCT06928883","Ticin Pilot Study: Sirolimus-Eluting Balloon for Stabilization and Regression of Non-Obstructive Coronary Plaques.","TITAN-PARADISE Pilot: TicIn for the Treatment of Coronary Lesions - Plaque Regression and Stabilization With Sirolimus Elution (Pilot Study)","Inclusion Criteria:\n\nPotential subjects must fulfill all following inclusion criteria:\n\n1. Multivessel coronary artery disease with ACS within 90 days prior to inclusion and successful interventional treatment of the culprit lesion\n2. Presence of ≥ 2 de novo non-culprit lesion without hemodynamic relevance in two different coronary vessels (demonstrated either by wire-based or angiography-based coronary physiology) and with MaxLCBI4mm ≥ 325 at baseline IVUS-NIRS\n3. Age ≥ 18 years\n4. Written informed consent\n\nExclusion Criteria:\n\nPatients are not eligible if any of the following applies:\n\n1. Non culprit lesion involving the left main and\u002For ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery;\n2. Non-culprit lesion in a previously stented segment (i.e. within 15 mm from the previously implanted stent);\n3. Non-culprit lesion involving small vessel (\\\u003C3.0 mm) deemed not suitable to PCI,\n4. Non-culprit lesion located in a bypass graft or in a grafted vessel;\n5. Severe renal impairment (eGFR\\\u003C15ml\u002Fmin\u002F1.73m2) or patient on dialysis treatment;\n6. Known pregnancy r breast-feeding patients;\n7. Life expectancy \\\u003C2 year due to other severe non-cardiac disease;\n8. Legally incompetent to provide informed consent;\n9. Partecipation in another clinical study with an investigational product",{"count":169,"type":21},24,[82],"The goal of this pilot clinical trial is to evaluate the use of the Selution SLR sirolimus-eluting balloon, in addition to guideline-directed medical therapy (GDMT), for the preventive treatment of non-flow-limiting vulnerable coronary lesions, compared to GDMT alone, in adult patients with multivessel coronary artery disease and a recent acute coronary syndrome (within 90 days).\n\nThe main research question is:\n\nDoes the use of the Selution SLR sirolimus-eluting balloon in combination with GDMT reduce the progression and vulnerability of non-flow-limiting vulnerable coronary plaques?\n\nParticipants will undergo\n\n* PCI procedure with baseline IVUS-NIRS assessment\n* Follow-up coronary angiography at 6 months with IVUS-NIRS assessment\n* Clinical follow-up at 3, 6, and 24 months after study enrollment",[173,174,175,176,177],"Coronary Arterial Disease (CAD)","Vulnerable Coronary Plaques","Multivessel Coronary Artery Disease","Coronary Vessel","Acute Coronary Syndromes (ACS)",[173,174,179,180,177,181,182,183,184,185,186,187,188],"Multivessel coronary artery disease","Coronary vessel","Non-flow limiting vulnerable coronary plaques","Sirolimus-eluting DEB","DEB Selution SLR","Guidelines-directed medical therapies (GDMT)","IVUS-NIRS","MaxLCBI4mm","MaxLCBI4mm≥325","Lipid Core Burden Index (LCBI)","NOT_YET_RECRUITING","2025-04-08",{"date":192,"type":63},"2025-04-15",{"date":194,"type":21},"2025-04",{"date":196,"type":21},"2028-12-31",{"name":69,"class":70},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":71},"100491092","phase-4-ticin-for-the-treatment-of-coronary-lesions-with-drug-eluting-ballons-100491092","NCT05674630","Ticin for the Treatment of Coronary Lesions With Drug Eluting Ballons","TicIn for the Treatment of coronAry lesioNs With Drug Eluting Balloons","TITAN-DEB","Inclusion Criteria:\n\n1. Adult patients (≥18 years old) with chronic coronary syndrome deemed suitable for PCI\n2. At least one significant de-novo coronary lesion (defined as diameter stenosis \\> 50% on angiography, with flow limiting features, confirmed with FFR ≤0.80 or iFR ≤0.89 and intended implantation of a long (≥30 mm) DES based on IVUS findings\n3. Written informed consent\n\nExclusion Criteria:\n\n1. Patients referred to the index procedure for an acute coronary syndrome\n2. Target lesion involving the left main and\u002For ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery\n3. Severe renal impairment (eGFR\\\u003C15ml\u002Fmin\u002F1.73m2) or patient on dialysis treatment\n4. Spontaneous coronary artery dissection (SCAD)\n5. Contraindications to adenosine administration (e.g. moderate to severe asthma or chronic obstructive pulmonary disease, heart rate \\\u003C50 beats\u002Fmin and systolic blood pressure \\\u003C90 mmHg)\n6. Known pregnancy or breast-feeding patients\n7. Life expectancy \\\u003C1 year due to other severe non-cardiac disease\n8. Legally incompetent to provide informed consent\n9. Participation in another clinical study with an investigational product",{"count":207,"type":21},130,[209],"PHASE4","The goal of this clinical trial is to compare the use of a specific drug eluting balloon (Magic Touch, Concept Medical®) versus standard drug eluting stent based strategies in patients with long coronary lesions.\n\nParticipants with chronic coronary disease and long coronary stenosis will be randomly assign to be treated either with Magic Touch balloon or drug eluting stent.",[212],"Chronic Coronary Syndrome",[214,215,216,217,218,219,220,221,222,223,224],"adult","chronic coronary syndrome","percutaneous intervention","significant de novo coronary lesion","FFR≤0.80","iFR≤0.89","long DES (≥30 mm)","coronary lesion","drug eluting balloon","drug eluting stent","Magic Touch drug eluting balloon","2023-09-06",{"date":227,"type":63},"2023-09-08",{"date":229,"type":63},"2023-02-21",{"date":231,"type":21},"2030-12-01",{"name":69,"class":70},""]